Author(s): Ashokraj Y, Kohli G, Kaul CL, Panchagnula R
Abstract Share this page
Abstract OBJECTIVE: To determine the quality and performance of rifampicin (RMP) containing fixed-dose combination (FDC) formulations of anti-tuberculosis drugs sourced from the international market with respect to physical, chemical and dissolution properties after storage at accelerated stability conditions (40 degrees C/75\% relative humidity) and to identify appropriate storage specifications. METHODS: Formulations across different companies and combinations were subjected to 6-month accelerated stability testing in packaging conditions recommended by the manufacturer. Various pharmacopeial and nonpharmacopeial tests for tablets were performed for 3- and 6-month samples. RESULTS: All the formulations were found to be stable, where extent of dissolution was within +/- 10\% of that of the initial value, and all formulations passed the pharmacopeial limits for assay and content uniformity of 90-110\% and +/- 15\% of average drug content, respectively. CONCLUSIONS: Good quality RMP-containing FDCs that remain stable after 6-month accelerated stability testing are available in the marketplace.
This article was published in Int J Tuberc Lung Dis
and referenced in Journal of Bioequivalence & Bioavailability